Arch Therapeutics Inc
OTC:ARTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arch Therapeutics Inc
Accrued Liabilities
Arch Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arch Therapeutics Inc
OTC:ARTH
|
Accrued Liabilities
$1.7m
|
CAGR 3-Years
113%
|
CAGR 5-Years
64%
|
CAGR 10-Years
22%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Accrued Liabilities
$52.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Accrued Liabilities
$227m
|
CAGR 3-Years
2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
23%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Accrued Liabilities
$492.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Accrued Liabilities
$249m
|
CAGR 3-Years
7%
|
CAGR 5-Years
43%
|
CAGR 10-Years
30%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Accrued Liabilities
$170.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
Arch Therapeutics Inc
Glance View
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. The company is headquartered in Framingham, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2012-06-27. The firm's technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and also referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body.
See Also
What is Arch Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
1.7m
USD
Based on the financial report for Jun 30, 2024, Arch Therapeutics Inc's Accrued Liabilities amounts to 1.7m USD.
What is Arch Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
22%
Over the last year, the Accrued Liabilities growth was 62%. The average annual Accrued Liabilities growth rates for Arch Therapeutics Inc have been 113% over the past three years , 64% over the past five years , and 22% over the past ten years .
